Results of point-of-care manufacturing of bispecific chimeric antigen receptor (CAR) LV20.19 CAR-TCELLS in a phase i study for relapsed/refractory (R/R), non-hodgkin lymphoma (NHL)
Zhu, F., Shah, N., Schneider, D., Xu, H., Chaney, K., Luib, L., Keever-Taylor, C., Dropulic, B., Orentas, R., Hari, P., Johnson, B.Volume:
21
Language:
english
Journal:
Cytotherapy
DOI:
10.1016/j.jcyt.2019.03.568
Date:
May, 2019
File:
PDF, 292 KB
english, 2019
File converter
More search results
More benefits 
